Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q7Z4W2
UPID:
LYZL2_HUMAN
Alternative names:
-
Alternative UPACC:
Q7Z4W2; Q6NZ69
Background:
Lysozyme-like protein 2, encoded by the gene with accession number Q7Z4W2, belongs to a family of enzymes known for their ability to cleave the glycosidic bonds within polysaccharides. This protein shares structural similarities with lysozymes, which are crucial for bacterial cell wall degradation.
Therapeutic significance:
Understanding the role of Lysozyme-like protein 2 could open doors to potential therapeutic strategies. Its structural resemblance to lysozymes suggests a possible involvement in antimicrobial defense mechanisms, making it a target for developing new antimicrobial agents.